Abstract
Optimising treatment strategies for patients with mCRC responding to first line chemotherapy has important connotations for quality of life, toxicity and prudent health care. Current standards in national guidelines support a strategy of ongoing chemotherapy until disease progression or excess toxicity. Trial level meta-analysis has indicated that complete treatment breaks may not detrimentally affect survival, however, breaks from treatment are not universally offered. FOCUS4-N explores the impact of oral capecitabine (C) maintenance in patients (pts) who are responding to first line therapy.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.